Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H23ClN2O2 |
Molecular Weight | 382.883 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)N1CCC(CC1)=C2C3=C(CCC4=C2N=CC=C4)C=C(Cl)C=C3
InChI
InChIKey=JCCNYMKQOSZNPW-UHFFFAOYSA-N
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
Molecular Formula | C22H23ClN2O2 |
Molecular Weight | 382.883 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Loratadine is a derivative of azatadine and a second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (histamine H1 antagonists) it lacks central nervous system depressing effects such as drowsiness. Loratadine competes with free histamine and exhibits specific, selective peripheral H1 antagonistic activity. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine. Loratadine has low affinity for cholinergic receptors and does not exhibit any appreciable alpha-adrenergic blocking activity in-vitro. Loratadine also appears to suppress the release of histamine and leukotrienes from animal mast cells, and the release of leukotrienes from human lung fragments, although the clinical importance of this is unknown.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=11023307
Curator's Comment: The second generation antihistamines were less soluble in lipid and thus less readily penetrated the blood-brain barrier
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7581058 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLARITIN Approved UseUses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: •runny nose •itchy, watery eyes •sneezing •itching of the nose or throat Launch Date7.3457277E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 ng/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
27.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/ |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
10.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.9 ng × h/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
96 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/ |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
34.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
14.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2958516/ |
40 mg 1 times / day steady-state, oral dose: 40 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22806583/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
LORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.5% |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 n = 103 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 29 Sex: M+F Population Size: 103 Sources: |
Other AEs: Somnolence, Headache... Other AEs: Somnolence (10%) Sources: Headache (9%) Fatigue (5%) Dry mouth (4%) |
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Other AEs: Fatigue, Fever... Other AEs: Fatigue (2%) Sources: Fever (7%) Headache (5%) Influenza-like symptoms (2%) Constipation (2%) Diarrhea (3%) Dyspepsia (2%) Loose stools (2%) Stomatitis (2%) Tooth disorder (2%) Vomiting (5%) Earache (2%) Drowsiness (7%) Infection viral (2%) Allergic rhinitis (2%) Coughing (3%) Epistaxis (3%) Pharyngitis (3%) Rash (2%) |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 35.3 n = 331 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 35.3 Sex: M+F Population Size: 331 Sources: |
Other AEs: Headache... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Somnolence | 10% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 n = 103 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 29 Sex: M+F Population Size: 103 Sources: |
Dry mouth | 4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 n = 103 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 29 Sex: M+F Population Size: 103 Sources: |
Fatigue | 5% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 n = 103 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 29 Sex: M+F Population Size: 103 Sources: |
Headache | 9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 29 n = 103 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 29 Sex: M+F Population Size: 103 Sources: |
Allergic rhinitis | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Constipation | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Dyspepsia | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Earache | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Fatigue | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Infection viral | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Influenza-like symptoms | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Loose stools | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Rash | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Stomatitis | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Tooth disorder | 2% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Coughing | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Diarrhea | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Epistaxis | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Pharyngitis | 3% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Headache | 5% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Vomiting | 5% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Drowsiness | 7% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Fever | 7% | 5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy, 3.6 n = 60 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 3.6 Sex: M+F Population Size: 60 Sources: |
Headache | 4.2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, 35.3 n = 331 Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 35.3 Sex: M+F Population Size: 331 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
no | |||
no | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 11.0 |
no | |||
no | ||||
yes [IC50 0.61 uM] | ||||
yes [IC50 0.76 uM] | ||||
yes [IC50 11 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/15601807/ Page: 6.0 |
yes [IC50 3.36 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10597902/ Page: 1,8 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/1534660/ Page: 1.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1.0 |
major | yes (co-administration study) Comment: Coadministration with either ketoconazole, erythromycin (both CYP3A4 inhibitors) increased AUC of drug by 307%, 40%, respectively; coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Page: 1.0 |
||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
minor | ||||
Page: 1.0 |
minor | yes (co-administration study) Comment: coadministration with cimetidine (CYP2D6 and CYP3A4 inhibitor) increased AUC of drug by 103% Page: 1.0 |
||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. | 1999 Dec |
|
Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. | 1999 Dec 15 |
|
Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. | 1999 Jan |
|
Mechanism responsible for epileptogenic activity by first-generation H1-antagonists in rats. | 2000 Dec 22 |
|
Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. | 2000 Jan |
|
Cetirizine and loratadine: a comparison using the ED50 in skin reactions. | 2000 Mar-Apr |
|
The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and weal and flare. | 2001 |
|
Treatment of urticaria. An evidence-based evaluation of antihistamines. | 2001 |
|
The pharmacologic profile of desloratadine: a review. | 2001 |
|
Desloratadine: a new approach in the treatment of allergy as a systematic disease--pharmacology and clinical overview. Introduction. | 2001 |
|
Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. | 2001 Aug |
|
Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. | 2001 Aug |
|
Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. | 2001 Jan |
|
Triamcinolone: new and old indications. | 2001 Jul |
|
FDA panel recommends OTC status for second-generation antihistamines. | 2001 Jul |
|
Evaluation of quality of life in children and teenagers with allergic rhinitis: adaptation and validation of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). | 2001 Jul-Aug |
|
An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers. | 2001 Mar |
|
Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. | 2001 Mar |
|
Children's school performance is not impaired by short-term administration of diphenhydramine or loratadine. | 2001 May |
|
Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus. | 2001 May 11 |
|
Determination of loratadine in human plasma by high-performance liquid chromatographic method with ultraviolet detection. | 2001 May 5 |
|
[Childhood asthma and viral infection: interactions and therapeutic possibilities]. | 2001 May-Jun |
|
Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. | 2001 Nov |
|
Inhibition of depolarization-induced [3H]noradrenaline release from SH-SY5Y human neuroblastoma cells by some second-generation H(1) receptor antagonists through blockade of store-operated Ca(2+) channels (SOCs). | 2001 Nov 1 |
|
Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold. | 2001 Nov 1 |
|
Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. | 2001 Nov 26 |
|
Effect of specific immunotherapy versus loratadine on serum adhesion molecules. | 2001 Oct |
|
Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. | 2001 Oct |
|
Do antihistamines impair school performance in children? | 2001 Sep |
|
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. | 2001 Sep |
|
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. | 2002 |
|
Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. | 2002 Apr |
|
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. | 2002 Feb |
|
Cardiotoxicity of new antihistamines and cisapride. | 2002 Feb 28 |
|
Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. | 2002 Jun |
|
Which is more effective for as-needed treatment of seasonal allergy symptoms: intranasal corticosteroids or oral antihistamines? | 2002 Mar |
|
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model. | 2002 Mar |
Sample Use Guides
Adults and children 6 years and over: 1 tablet daily; not more than 1 tablet in 24 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7510965
dose-dependent inhibition of histamine release was observed at loratadine dose above 7 UM. In the rat basophilic leukemia cells (RBL-2H3) experimental system, inhibition by loratadine increased when the concentration of extracellular Ca2+ was reduced from 1.8 to 0.45 mM. Loratadine also inhibited the Mn2+ influx into these cells, thus reflecting the Ca2+ influx.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:25:11 UTC 2022
by
admin
on
Fri Dec 16 17:25:11 UTC 2022
|
Record UNII |
7AJO3BO7QN
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R06AX13
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
||
|
WHO-VATC |
QR06AX13
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
||
|
LIVERTOX |
NBK548831
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID2023224
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
7216
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
758628
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
5864
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
79794-75-5
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
1370270
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
3957
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
M6905
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | Merck Index | ||
|
1605
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
D017336
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
Loratadine
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
7AJO3BO7QN
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
SUB08581MIG
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
3578
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
W-119
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
28889
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | RxNorm | ||
|
CHEMBL998
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
7AJO3BO7QN
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
DB00455
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
LORATADINE
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY | |||
|
C29162
Created by
admin on Fri Dec 16 17:25:11 UTC 2022 , Edited by admin on Fri Dec 16 17:25:11 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
PARENT->INNOVATOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (GC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||